Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) – Analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of Tandem Diabetes Care in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky expects that the medical device company will earn ($0.01) per share for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2028 earnings at $0.27 EPS.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The firm had revenue of $221.90 million during the quarter, compared to the consensus estimate of $205.63 million. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.30) earnings per share.
View Our Latest Analysis on Tandem Diabetes Care
Tandem Diabetes Care Price Performance
TNDM stock opened at $34.81 on Thursday. The company has a fifty day moving average price of $42.02 and a 200-day moving average price of $41.84. The company has a market capitalization of $2.28 billion, a P/E ratio of -16.66 and a beta of 1.33. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $53.69. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.38 and a current ratio of 3.05.
Institutional Investors Weigh In On Tandem Diabetes Care
Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its holdings in Tandem Diabetes Care by 1,481.5% in the first quarter. BNP Paribas Financial Markets now owns 145,812 shares of the medical device company’s stock worth $5,163,000 after purchasing an additional 136,592 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Tandem Diabetes Care during the first quarter valued at about $540,000. Vanguard Group Inc. grew its holdings in shares of Tandem Diabetes Care by 0.4% during the first quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock valued at $249,732,000 after buying an additional 30,664 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Tandem Diabetes Care during the first quarter valued at about $5,227,000. Finally, Quantbot Technologies LP acquired a new position in shares of Tandem Diabetes Care during the first quarter valued at about $710,000.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Further Reading
- Five stocks we like better than Tandem Diabetes Care
- What Investors Need to Know About Upcoming IPOs
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Business Services Stocks Investing
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Canada Bond Market Holiday: How to Invest and Trade
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.